Azithromycin/loteprednol-etabonate

Drug Profile

Azithromycin/loteprednol-etabonate

Alternative Names: Azithromycin/loteprednol; Loteprednol-etabonate/azithromycin; Loteprednol/azithromycin

Latest Information Update: 08 Jan 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adapt Produtos Oftalmologicos
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Bacterial infections; Infectious conjunctivitis; Keratitis; Ocular inflammation

Most Recent Events

  • 01 Dec 2014 Adapt terminates phase III trial in Ocular inflammation and infection in Brazil (NCT01721694) prior to initiation
  • 03 Jan 2013 Adapt Produtos Oftalmologicos plans a phase III trial for Ocular inflammation and infections in Brazil (NCT01721694)
  • 05 Nov 2012 Clinical trials in Bacterial infections in Brazil (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top